
Zymeworks ZYME
$ 26.58
-1.08%
Quarterly report 2022-Q2
added 12-23-2023
Zymeworks Operating Expenses 2011-2025 | ZYME
Annual Operating Expenses Zymeworks
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 226 K | 180 M | 86.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 180 M | 226 K | 88.8 M |
Quarterly Operating Expenses Zymeworks
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 53.2 M | 76.3 M | 52.7 M | 44.1 M | 75.6 M | 41.4 M | 37.3 M | 26.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 76.3 M | 26.5 M | 50.9 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Aptevo Therapeutics
APVO
|
-31.8 M | $ 0.56 | -7.58 % | $ 155 K | ||
|
Aclaris Therapeutics
ACRS
|
92.7 M | $ 3.03 | - | $ 234 M | ||
|
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.19 | 0.63 % | $ 7.68 B | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.82 | 8.68 % | $ 464 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
20.7 M | $ 1.13 | -0.47 % | $ 6.16 M | ||
|
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 210.42 | 0.69 % | $ 5 B | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
BioVie
BIVI
|
18.1 M | $ 1.19 | -2.07 % | $ 1.76 M | ||
|
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 0.19 | -13.09 % | $ 413 M | ||
|
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
512 M | $ 94.4 | -0.13 % | $ 27.2 B | ||
|
Catalyst Biosciences
CBIO
|
176 M | $ 12.31 | -0.32 % | $ 810 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 26.88 | -0.89 % | $ 1.3 B | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
125 M | - | -10.95 % | $ 876 K | ||
|
Anika Therapeutics
ANIK
|
51.6 M | $ 9.53 | -0.21 % | $ 140 M | ||
|
Certara
CERT
|
232 M | $ 8.87 | -0.22 % | $ 1.42 B | ||
|
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | ||
|
Cellectis S.A.
CLLS
|
109 M | $ 4.92 | 3.47 % | $ 116 M | ||
|
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Axon Enterprise
AXON
|
1.18 B | $ 580.25 | -0.61 % | $ 44 B | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
53.7 M | $ 2.49 | 1.43 % | $ 15.6 M | ||
|
AstraZeneca PLC
AZN
|
17.6 B | $ 92.65 | -0.27 % | $ 96.9 B | ||
|
ChromaDex Corporation
CDXC
|
53.9 M | - | -0.88 % | $ 598 M | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
106 M | $ 9.22 | 1.43 % | $ 1.49 B | ||
|
Celldex Therapeutics
CLDX
|
58.1 M | $ 26.01 | -1.5 % | $ 1.67 M |